The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine

Vaccine

Volumn 25, Issue 51, 2007, Pages 8549-8556

  Hui, George ^a   Hashimoto, Caryn ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Adjuvants; B7 1; B7 2; CD54; CD80; CD86; Co stimulatory molecules; ICAM 1; Immunomodulators; Intercellular adhesion molecule 1; Malaria vaccine; Merozoite surface protein 1; MSP1; Plasmodium falciparum

Indexed keywords

CD8 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; ISA 720; MALARIA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; QS 21; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENTIATION; EMULSION; FEMALE; IMMUNOGENICITY; IMMUNOMODULATION; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, PROTOZOAN; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-4; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMODIUM FALCIPARUM; SPLEEN;

EID: 36549044922     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.010     Document Type: Article

References (60)

1. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2 9 (2003) 727-735
2. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11 (2005) s63-s68
3. Singh M., and O'Hagan D.T. Recent advances in veterinary vaccine adjuvants. Int J Parasitol 33 5-6 (2003) 469-478
4. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168 2 (2002) 926-932
5. Masopust D., and Ahmed R. Reflections on CD8 T cell activation and memory. Immunol Res 29 1-3 (2004) 151-160
6. Schepers K., Arens R., and Schumacher T.N. Dissection of cytotoxic and helper T cell responses. Cell Mol Life Sci 62 23 (2005) 2695-2710
7. Stager S., and Kaye P.M. CD8+ T cell priming regulated by cytokines of the innate immune system. Trends Mol Med 10 8 (2004) 366-371
8. Zammit D.J., and Lefrancois L. Dendritic cell-T cell interactions in the generation and maintenance of CD8 T cell memory. Microbes Infect 8 4 (2006) 1108-1115
9. Fujii S., Shimizu K., Hemmi H., Fukui M., Bonito A.J., Chen G., et al. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA 103 30 (2006) 11252-11257
10. Fujii Si, Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 2 (2003) 267-279
11. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171 10 (2003) 5140-5147
12. Johnson D.A., Keegan D.S., Sowell C.G., Livesay M.T., Johnson C.L., Taubner L.M., et al. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J Med Chem 42 22 (1999) 4640-4649
13. Okemoto K., Kawasaki K., Hanada K., Miura M., and Nishijima M. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. J Immunol 176 2 (2006) 1203-1208
14. Silk J.D., Hermans I.F., Gileadi U., Chong T.W., Shepherd D., Salio M., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114 12 (2004) 1800-1811
15. Thompson B.S., Chilton P.M., Ward J.R., Evans J.T., and Mitchell T.C. The low-toxicity versions of LPS, MPL(R) adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol 78 6 (2005) 1273-1280
16. Tsuji M., and Glycolipids. Phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol Life Sci 63 16 (2006) 1889-1898
17. Ulrich J.T., and Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 6 (1995) 495-524
18. Hermans I.F., Silk J.D., Gileadi U., Masri S.H., Shepherd D., Farrand K.J., et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol 178 5 (2007) 2721-2729
19. Hui G.S., and Hashimoto C.N. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. Infect Immunol 66 11 (1998) 5329-5336
20. Hui G., and Hashimoto C. Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine. Vaccine 25 36 (2007) 6598-6603
21. Brady C.P., Shimp R.L., Miles A.P., Whitmore M., and Stowers A.W. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris. Protein Exp Purif 23 3 (2001) 468-475
22. Croft M., and Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol 17 1 (1997) 89-118
23. Collins M., Ling V., and Carreno B.M. The B7 family of immune-regulatory ligands. Genome Biol 6 6 (2005) 223
24. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
25. Wang S., and Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family. Cell Mol Immunol 1 1 (2004) 37-42
26. Anderson M.E., and Siahaan T.J. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 24 3 (2003) 487-501
27. Lebedeva T., Dustin M.L., and Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 17 3 (2005) 251-258
28. Wingren A.G., Parra E., Varga M., Kalland T., Sjogren H.O., Hedlund G., et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 15 3-4 (1995) 235-253
29. Agrawal A., Lingappa J., Leppla S.H., Agrawal S., Jabbar A., Quinn C., et al. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424 6946 (2003) 329-334
30. Chen X., He J., and Chang L.J. Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology 1 (2004) 37
31. Fischer H.G., Dorfler R., Schade B., and Hadding U. Differential CD86/B7-2 expression and cytokine secretion induced by Toxoplasma gondii in macrophages from resistant or susceptible BALB H-2 congenic mice. Int Immunol 11 3 (1999) 341-349
32. Gupta S., Vohra H., Saha B., Nain C.K., and Ganguly N.K. Macrophage-T cell interaction in murine salmonellosis: selective down-regulation of ICAM-1 and B7 molecules in infected macrophages and its probable role in cell-mediated immunity. Eur J Immunol 26 3 (1996) 563-570
33. Kaye P.M., Rogers N.J., Curry A.J., and Scott J.C. Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages. Eur J Immunol 24 11 (1994) 2850-2854
34. Lambert H., Hitziger N., Dellacasa I., Svensson M., and Barragan A. Induction of dendritic cell migration upon Toxoplasma gondii infection potentiates parasite dissemination. Cell Microbiol 8 10 (2006) 1611-1623
35. Mencacci A., Cenci E., Del Sero G., d'Ostiani Fe C., Mosci P., Montagnoli C., et al. Defective co-stimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin-alpha double-deficient mice infected with Candida albicans. Int Immunol 10 1 (1998) 37-48
36. Planelles L., Thomas M.C., Maranon C., Morell M., and Lopez M.C. Differential CD86 and CD40 co-stimulatory molecules and cytokine expression pattern induced by Trypanosoma cruzi in APCs from resistant or susceptible mice. Clin Exp Immunol 131 1 (2003) 41-47
37. Ubol S., Aiamkitsumrit B., Nitayaphan S., Sirinavin S., and Kitthawee S. Detection of the impairment of CD80 expression on circulating monocytes in HIV-infected Thai children. Microbiol Immunol 48 7 (2004) 557-560
38. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199 (2004) 227-250
39. Chang S.P., Hui G.S., Kato A., and Siddiqui W.A. Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum. Proc Natl Acad Sci USA 86 16 (1989) 6343-6347
40. Lawrence G.W., Saul A., Giddy A.J., Kemp R., and Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15 2 (1997) 176-178
41. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., and Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6 (1995) 277-296
42. Kensil C.R., Wu J.Y., and Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol 6 (1995) 525-541
43. Childers N.K., Miller K.L., Tong G., Llarena J.C., Greenway T., Ulrich J.T., et al. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immunol 68 10 (2000) 5509-5516
44. Skeiky Y.A., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20 27-28 (2002) 3292-3303
45. Hui G.S., Chang S.P., Gibson H., Hashimoto A., Hashiro C., Barr P.J., et al. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. J Immunol 147 11 (1991) 3935-3941
46. Kaslow D.C., Hui G., and Kumar S. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol 63 2 (1994) 283-289
47. Favre N., Bordmann G., and Rudin W. Comparison of cytokine measurements using ELISA, ELISPOT and semi-quantitative RT-PCR. J Immunol Methods 204 1 (1997) 57-66
48. Nagabhushanam V., and Cheers C. Non-major histocompatibility complex control of antibody isotype and Th1 versus Th2 cytokines during experimental infection of mice with Mycobacterium avium. Infect Immunol 69 3 (2001) 1708-1713
49. Su H.C., Cousens L.P., Fast L.D., Slifka M.K., Bungiro R.D., Ahmed R., et al. CD4+ and CD8+ T cell interactions in IFN-gamma and IL-4 responses to viral infections: requirements for IL-2. J Immunol 160 10 (1998) 5007-5017
50. Miyahira Y., Murata K., Rodriguez D., Rodriguez J.R., Esteban M., Rodrigues M.M., et al. Quantification of antigen-specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181 1 (1995) 45-54
51. Podojil J.R., and Sanders V.M. Selective regulation of mature IgG1 transcription by CD86 and beta 2-adrenergic receptor stimulation. J Immunol 170 10 (2003) 5143-5151
52. Podojil J.R., Kin N.W., and Sanders V.M. CD86 and beta2-adrenergic receptor signaling pathways, respectively, increase Oct-2 and OCA-B expression and binding to the 3′-IgH enhancer in B cells. J Biol Chem 279 22 (2004) 23394-23404
53. Suvas S., Singh V., Sahdev S., Vohra H., and Agrewala J.N. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 277 10 (2002) 7766-7775
54. Pink JR, Kieny MP. Proceedings of the fourth meeting on novel adjuvants currently in/close to human clinical testing: World Health Organization-Organization Mondiale de la Sante Fondation Merieux, Annecy, France, June 23-25, 2003. Vaccine 2004;22(17-18):2097-102.
55. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., et al. B7-1 and B7-2 co-stimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80 5 (1995) 707-718
56. Figdor C.G. Molecular characterization of dendritic cells operating at the interface of innate or acquired immunity. Pathol Biol (Paris) 51 2 (2003) 61-63
57. van Kooyk Y., and Geijtenbeek T.B. A novel adhesion pathway that regulates dendritic cell trafficking and T cell interactions. Immunol Rev 186 (2002) 47-56
58. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immunol 64 1 (1996) 253-261
59. Hui G.S., and Siddiqui W.A. Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro. Exp Parasitol 64 3 (1987) 519-522
60. Singh S., Miura K., Zhou H., Muratova O., Keegan B., Miles A., et al. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immunol 74 8 (2006) 4573-4580